Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Melanoma 1

Interventions

pembrolizumab 64Nivolumab 55Ipilimumab 34Specimen Handling 23Magnetic Resonance Spectroscopy 21Cyclophosphamide 16Biopsy 13Radiosurgery 12relatlimab 11CTLA-4 Antigen 11trametinib 10fludarabine 10binimetinib 10Opdualag 10dabrafenib 8lifileucel 7fludarabine phosphate 7encorafenib 7aldesleukin 7atezolizumab 6Interleukin-2 6cemiplimab 5X-Rays 5Paclitaxel 5Immunoglobulin G 5Blood Specimen Collection 5Taxes 4Radiotherapy 4Pemetrexed 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × famitinib × 90 days × Clear all
NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡